MindImmune Therapeutics
Kingston, US · Founded 2016 · Delaware corporation · 4 known investors
Find your way into MindImmune Therapeutics
157 people in our graph share verified history with the MindImmune Therapeutics team — schools, employers, funds. One of them is your warm intro.
Thorne Sparkmanunlockedknows Isaac Stoner · together at Slater Technology Fund (overlapped)
knows the team · via Slater Technology Fund
×2knows the team · via PureTech Health
×3knows the team · via Rockefeller University
×2knows the team · via Martin Trust Center for MIT Entrepreneurship
×2knows the team · via Lafayette College
Founders & leadership
MindImmune Therapeutics was founded in 2016 by Robert B. Nelson, Frank S. Menniti, and Stevin Zorn.
RB
Robert B. NelsonCo-founder
FS
Frank S. MennitiinFounder, Chief Science Officer2016–2026
SZ
Stevin ZorninFounder and AdvisorStevin Zorn held roles at Pfizer and Lundbeck in pharmaceutical R&D and served as a university professor before becoming an executive officer at MindImmune Therapeutics, a biotech company focused on neuropsychiatric drug development.
IS
Isaac StonerinChief Executive Officer
Board
RG
Richard G. HoranBoard director
RB
Reetika BhardwajBoard director
CO
Christopher O'DonnellBoard director
BM
Bradley MargusBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$21.3M disclosed across 3 rounds · 2019–2025
▶$15.2MraisedMar 2026 · 15 investors · PharmaceuticalsRule 506(b)
▶$15.2MraisedMar 2026 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Reetika BhardwajDirector
- Christopher O'DonnellDirector
- Bradley MargusDirector
- Isaac StonerExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $15.2M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.3MraisedFeb 2022 · 12 investors · PharmaceuticalsRule 506(b)
▶$5.3MraisedFeb 2022 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert B. NelsonExecutive Officer
- Christopher O'DonnellDirector
- Tracy SaxtonDirector
- Stevin ZornExecutive Officer, Director
- Diane GoodingExecutive Officer
- Offering amount
- $8.9M
- Amount sold
- $5.3M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedNov 2019 · 8 investors · PharmaceuticalsRule 506(b)
▶$750KraisedNov 2019 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert B. NelsonExecutive Officer, Director
- Frank S. MennitiExecutive Officer, Director
- Richard G. HoranDirector
- Stevin ZornExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $750K
- Proceeds to insiders
- $875K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded MindImmune Therapeutics?
- MindImmune Therapeutics was founded by Robert B. Nelson, Frank S. Menniti, Stevin Zorn in 2016.
- Who are MindImmune Therapeutics's investors?
- MindImmune Therapeutics's investors include Pfizer Venture Investments, Dolby Family Ventures, Pfizer Ventures, Slater Technology Fund.
- How much funding has MindImmune Therapeutics raised?
- MindImmune Therapeutics has disclosed $21.3M raised across 3 rounds.
- Where is MindImmune Therapeutics headquartered?
- MindImmune Therapeutics is headquartered in Kingston, US.